RG-239 is an orally active TGR5 agonist with an EC50 of 120 nM, significantly outperforming Betulinic acid (HY-10529) (EC50 = 1.04 µM). RG-239 demonstrates higher selectivity for TGR5 compared to the FXRalpha. RG-239 increases mitochondrial activity in adipocytes and promotes neurite outgrowth at higher concentrations. RG-239 inhibits LPS (HY-D1056)-induced iNOS expression and nitrite production in Raw264.7 and microglia cells. RG-239 can be used for the study of type 2 diabetes[1][2][3][4][5].
Molecular Weight:
496.76
CAS Number:
[1199222-56-4]
Formula:
C33H52O3
Target:
G protein-coupled Bile Acid Receptor 1
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
